lim kinase

LX7101 is an effective inhibitor of LIMK and ROCK2 (IC50: 24, 1.6, and 10 nM for LIMK1, LIMK2, and ROCK2, respectively). It also inhibits PKA (IC50 <1 nM).

R-10015 is a highly potent and selective LIMK inhibitor that blocks LIMK by binding to the ATP-binding pocket. It inhibits human LIMK1 with an IC50 value of 38 nM. It also exerts broad-spectrum antiviral effects and may be used in HIV infection research.

LIMK-IN-22j (LIMK inhibitor 22j) is an effective and selective inhibitor of LIMK.

T56-LIMKi (T5601640) is a selective inhibitor of LIMK2.

BMS-3 is a potent LIMK inhibitor with IC50 values of 5 nM and 6 nM for LIMK1 and LIMK2, respectively.

BMS-5 (LIMKi 3) is a highly potent LIMK inhibitor, exhibiting IC50 values of 7 nM for LIMK1 and 8 nM for LIMK2.

Aurora LIM kinase-IN-1 (Compound F114) is a potent dual inhibitor of aurora and LIM kinases. It inhibits the proliferation and invasion of glioblastoma multiforme (GBM), making it a potential candidate for drug development in GBM and other cancers. Aurora and LIM kinases are involved in neoplastic cell division and cell motility, respectively [1].

Damnacanthal is a natural anthraquinone compound with potential anticancer, anti-inflammatory, antioxidant, anti-malarial, and antiviral effects.Damnacanthal inhibits a variety of protein kinases such as LIMK1 (IC50=0.8 μM), LIMK2 (IC50=1.5 μM), and Lck (IC50=17 nM), and inhibits the growth of human hepatocellular carcinoma (SKHep-1) and human breast cancer (MCF-7) cells.

LX-7101 hydrochloride is a potent LIMK and ROCK2 inhibitor with antihypertensive activity, inhibits LIMK1 2, ROCK, PKA, and can be used to study glaucoma.

LY2812223 is a highly effective and functionally selective mGlu2 receptor agonist. It has a mGlu2 binding affinity for mGlu2 and mGlu3 (Ki=144 nM and 156 nM, respectively).

CRT-0105950 is a potent LIMK inhibitor with high affinity for both LIMK1 and LIMK2.CRT-0105950 inhibits filamentous cutin phosphorylation and promotes α-microtubulin acetylation in cells.CRT-0105950 can be used in the study of renal carcinoma.

SM1-71 is a potent multi-targeted acrylamide-modified TAK1 inhibitor that inhibits MKNK2, MAP2K1 2 3 4 6 7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A B, MAPK1 3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2.SM1-71 can be used as a kinase probe with anticancer activity and inhibits the proliferation of various cancer cell lines.

TH-257 is a Potent and selective allosteric LIMK 1 2 inhibitor(LIMK1 and LIMK2, IC50 of 84 nM and 39 nM).

LIMK1 inhibitor BMS-4 is a compound targeting LIM Kinase (LIMK) 1 2, specifically inhibiting the phosphorylation of its substrate cofilin, while remaining noncytotoxic on A549 cells.

TH470, a potent and highly selective inhibitor of LIM kinase 1 2 (LIMK1 2), demonstrates specificity with IC50 values of 9.8 nM for LIMK1 and 13 nM for LIMK2, making it applicable in orphan disease research.

S3 Fragment is a biologically active peptide featuring the amino-terminal phosphorylation site unique to Xenopus ADF cofilin, which is the target of LIM kinase (LIMK) phosphorylation. LIMK1, a pivotal regulator of the actin cytoskeleton, phosphorylates ADF cofilin at serine-3, leading to its inactivation. As a segment of the S3 peptide harboring the serine-3 sequence, this fragment serves as a widely recognized competitive inhibitor of LIMK1.

LX7101 is a potent inhibitor of both LIM kinase (LIMK) 1 and 2, and Rho-associated kinase 1 (ROCK1) and ROCK2, with IC50 values of 32, 4.3, 69, and 32 nM, respectively. It is selective, demonstrated by its lack of cross-reactivity in a panel of binding assays involving 78 receptors, transporters, and an additional 430 kinases, at a concentration of 10 μM. The topical administration of LX7101 (3 μl of a 1 mg ml solution) to the eye has been shown to reduce intraocular pressure in a dexamethasone-induced mouse model of glaucoma.

LIMK1 inhibitor 2 (compound 41) is a LIMK1 inhibitor with an IC50 value of 9 μM.

LIMK1 inhibitor1 (compound 24) is a LIMK1 inhibitor, potentially useful for cancer research.

MDI-114215 (compound 85) serves as an allosteric dual inhibitor of LIMK1 2 and exhibits favorable in vivo tolerance. It is capable of inhibiting the phosphorylation of cofilin in mouse brain region-induced pluripotent stem cells (iPSCs) and can be utilized in Fragile X Syndrome (FXS) research.

CRT-0105446 is an effective LIMK inhibitor that acts by suppressing cofilin phosphorylation and increasing αTubulin acetylation in cells.

SR7826 is a selective LIMK inhibitor.

DB1113 (Example 24) is a bifunctional compound designed for the targeted degradation of various kinases, including ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. This capability positions DB1113 as a valuable tool for research into diseases or disorders associated with aberrant kinase activity [1].

RSS0680 is a protein kinase degrader that degrades a variety of kinases and can be used to study diseases caused by kinase abnormalities.